Lanark, United Kingdom

Duncan R Rae

This inventor holds 13 USPTO granted patents. Top assignees: Akzo N.v., Akzo Nobel N.v., Akzona Incorporated. Active years: 1979-2002.


% Patents Active = 100.0

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 43(Granted Patents)


Location History:

  • Lanarkshire, GB (1994 - 2000)
  • Lanark, GB (1979 - 2002)

Company Filing History:


Years Active: 1979-2002

Loading Chart...
13 patents (USPTO):Explore Patents

Title: Duncan R Rae: Pioneering Inventor from Lanark, GB

Introduction: Duncan R Rae, a prolific inventor hailing from Lanark, GB, has made significant contributions to the field of pharmaceuticals through his innovative patented inventions.

Latest Patents: Among Duncan R Rae's 13 patents, his latest notable inventions include "Antipsychotic substituted piperidine derivatives" and "Benzylamine derivatives for treating psychiatric disorders." These benzylamine derivatives are instrumental in the treatment of psychiatric disorders, particularly depression.

Career Highlights: Duncan R Rae has worked with esteemed companies such as Akzo N.V. and Akzo Nobel N.V., where he honed his skills and made groundbreaking advancements in the pharmaceutical industry. His patents reflect his dedication to developing novel solutions for complex medical conditions.

Collaborations: Throughout his career, Duncan R Rae collaborated with talented individuals in the field, including coworkers Samuel George Gibson and James Cairns. These collaborations have led to the successful implementation of innovative ideas and the development of groundbreaking pharmaceutical products.

Conclusion: Duncan R Rae's journey as an inventor showcases his commitment to pushing the boundaries of pharmaceutical research and development. His patents stand as a testament to his ingenuity and passion for improving medical therapies, ultimately making a positive impact on patients' lives worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…